AU2017223838B2 - Treatment of neurodegenerative eye disease using pridopidine - Google Patents

Treatment of neurodegenerative eye disease using pridopidine Download PDF

Info

Publication number
AU2017223838B2
AU2017223838B2 AU2017223838A AU2017223838A AU2017223838B2 AU 2017223838 B2 AU2017223838 B2 AU 2017223838B2 AU 2017223838 A AU2017223838 A AU 2017223838A AU 2017223838 A AU2017223838 A AU 2017223838A AU 2017223838 B2 AU2017223838 B2 AU 2017223838B2
Authority
AU
Australia
Prior art keywords
pridopidine
subject
eye
administration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017223838A
Other languages
English (en)
Other versions
AU2017223838A1 (en
Inventor
Michal Geva
Ralph Laufer
Aric ORBACH
Hermann Kurt Russ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prilenia Neurotherapeutics Ltd
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of AU2017223838A1 publication Critical patent/AU2017223838A1/en
Assigned to PRILENIA THERAPEUTICS DEVELOPMENT LTD. reassignment PRILENIA THERAPEUTICS DEVELOPMENT LTD. Request for Assignment Assignors: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Assigned to PRILENIA NEUROTHERAPEUTICS LTD. reassignment PRILENIA NEUROTHERAPEUTICS LTD. Amend patent request/document other than specification (104) Assignors: PRILENIA THERAPEUTICS DEVELOPMENT LTD.
Application granted granted Critical
Publication of AU2017223838B2 publication Critical patent/AU2017223838B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017223838A 2016-02-24 2017-02-24 Treatment of neurodegenerative eye disease using pridopidine Active AU2017223838B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662299290P 2016-02-24 2016-02-24
US62/299,290 2016-02-24
PCT/US2017/019266 WO2017147366A1 (en) 2016-02-24 2017-02-24 Treatment of neurodegenerative eye disease using pridopidine

Publications (2)

Publication Number Publication Date
AU2017223838A1 AU2017223838A1 (en) 2018-09-06
AU2017223838B2 true AU2017223838B2 (en) 2022-09-29

Family

ID=59686581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017223838A Active AU2017223838B2 (en) 2016-02-24 2017-02-24 Treatment of neurodegenerative eye disease using pridopidine

Country Status (10)

Country Link
US (1) US11738012B2 (enExample)
EP (1) EP3419622B1 (enExample)
JP (1) JP7034488B2 (enExample)
AU (1) AU2017223838B2 (enExample)
CA (1) CA3015512C (enExample)
DK (1) DK3419622T3 (enExample)
ES (1) ES2979123T3 (enExample)
HU (1) HUE066769T2 (enExample)
PL (1) PL3419622T3 (enExample)
WO (1) WO2017147366A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US20220062255A1 (en) * 2016-02-24 2022-03-03 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
BR112019003731A2 (pt) 2016-08-24 2019-07-16 Prilenia Therapeutics Dev Ltd aplicação de pridopidina para tratamento de distonias
JP6912574B2 (ja) 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
MX383462B (es) 2017-09-08 2025-03-14 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de las discinesias inducidas por fármacos
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12357624B2 (en) 2019-02-04 2025-07-15 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
CA3128250C (en) * 2019-03-15 2024-01-16 Michael Hayden Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
JP2024536181A (ja) * 2021-10-11 2024-10-04 プリレニア ニューロセラピューティクス リミテッド 神経変性眼疾患を治療するためのプリドピジン及びその類似体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
IL134241A (en) * 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
WO2004103263A2 (en) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
BRPI0810161A2 (pt) 2007-04-12 2014-12-30 Nsab Af Neurosearch Sweden Ab Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
CA2688439A1 (en) 2007-05-31 2008-12-11 Joseph Weinstock Treatment of age-related macular degeneration
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
EP2753603B1 (en) 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
EA027748B1 (ru) 2012-04-04 2017-08-31 Тева Фармасьютикалз Интернэшнл Гмбх Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения
CA2884260A1 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
HUE058288T2 (hu) 2014-01-22 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin módosított hatóanyag-leadású készítményei
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3590512A1 (en) 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
KR20200031446A (ko) 2018-09-14 2020-03-24 삼성전자주식회사 무선 통신 시스템에서 pdcch 모니터링 방법 및 장치

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mueller, B (2014) 'Neuroprotective properties of sigma-1 receptor in glaucoma' [obtained from internet on 03 November 2021] <URL: http://digitalcommons.hsc.unt.edu/cgi/viewcontent.cgi?article=1758&context=theses> *
Sahlholm, K et al (2015) "Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses." Psychopharmacology 232(18): 3443-53. doi:10.1007/s00213-015-3997-8 *

Also Published As

Publication number Publication date
PL3419622T3 (pl) 2024-07-08
ES2979123T3 (es) 2024-09-24
EP3419622A1 (en) 2019-01-02
CA3015512A1 (en) 2017-08-31
EP3419622A4 (en) 2019-07-10
CA3015512C (en) 2024-01-16
US20190046516A1 (en) 2019-02-14
HUE066769T2 (hu) 2024-09-28
EP3419622B1 (en) 2024-03-06
US11738012B2 (en) 2023-08-29
JP7034488B2 (ja) 2022-03-14
AU2017223838A1 (en) 2018-09-06
WO2017147366A1 (en) 2017-08-31
JP2019507758A (ja) 2019-03-22
DK3419622T3 (da) 2024-06-03

Similar Documents

Publication Publication Date Title
AU2017223838B2 (en) Treatment of neurodegenerative eye disease using pridopidine
JP2019518730A (ja) 眼の炎症性障害および疾患の組合せ処置
US12208091B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
US11654140B2 (en) Treatment of ocular inflammatory diseases using laquinimod
US20180140593A1 (en) Treatment of Glaucoma Using Laquinimod
US20220062255A1 (en) Treatment of neurodegenerative eye disease using pridopidine
US20240261273A1 (en) Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
Mashael Systemic Medications and Their Ocular Side Effects
AU2025217391A1 (en) Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
HK40061312A (en) Compounds for treatment of eye diseases associated with excessive vascularisation
HK40061312B (en) Compounds for treatment of eye diseases associated with excessive vascularisation

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PRILENIA THERAPEUTICS DEVELOPMENT LTD.

Free format text: FORMER APPLICANT(S): TEVA PHARMACEUTICALS INTERNATIONAL GMBH

HB Alteration of name in register

Owner name: PRILENIA NEUROTHERAPEUTICS LTD.

Free format text: FORMER NAME(S): PRILENIA THERAPEUTICS DEVELOPMENT LTD.

FGA Letters patent sealed or granted (standard patent)